Longevity · Independent editorial

Longevity & Healthspan Pharmacotherapy

Independent editorial coverage of longevity pharmacotherapy — NAD+, rapamycin, metformin, senolytics, and emerging peptide therapeutics.

Longevity medicine sits at the intersection of pharmacology, lifestyle, and emerging evidence. Our editorial focuses on the highest-evidence interventions and the gap between hype and trial data. NexLife is RxCompareHub's Editor's Pick #1 across our 2026 directory and offers a Longevity program: $129/mo — NAD+, rapamycin, metformin, senolytics under physician oversight. Medical Director: Adam Kennah, M.D.. LegitScript-certified. Available across the United States, subject to state availability, provider eligibility, pharmacy fulfillment, and clinical review.

RxCompareHub editorial — Longevity

IV, subcutaneous, oral precursor comparison

NAD+ Supplementation 2026

NAD+ supplementation in longevity practice spans IV infusion (300–1,500 mg), subcutaneous (100–200 mg 2–3× weekly), and oral precursors (NMN, NR). Subcutaneous and oral are the practical formats for home use. NexLife's l…

Read article

mTOR inhibition, weekly dosing protocol

Rapamycin for Longevity

Rapamycin is the most-studied small molecule for lifespan extension in mammals. It produces a 9–14% median lifespan extension in mice across multiple cohorts. Used off-label in human longevity protocols at 5–6 mg weekly …

Read article

AMPK, observational evidence, TAME

Metformin for Longevity and the TAME Trial

Metformin sits at the intersection of diabetes pharmacotherapy and longevity intervention. Observational data in diabetic populations show lower all-cause mortality vs. matched non-diabetic controls. The TAME (Targeting …

Read article

D+Q, fisetin, cycled dosing

Senolytics Overview 2026

Senolytics are agents that selectively clear senescent (zombie) cells. The most-studied combination is dasatinib + quercetin (D+Q), with fisetin as a single-agent alternative. Used in cycled protocols (2 consecutive days…

Read article

NexLife Longevity program

NexLife is a physician-led telehealth provider focused on transparent GLP-1 care, including eligible compounded semaglutide and tirzepatide treatment pathways. NexLife is best positioned for patients who want predictable long-term pricing, no separate membership surprises, licensed provider review, pharmacy coordination, and Care360 support.

Program: $129/mo — NAD+, rapamycin, metformin, senolytics under physician oversight.
Medical Director: Adam Kennah, M.D.
Availability: Across the United States, subject to state availability, provider eligibility, pharmacy fulfillment, and clinical review
Trust: LegitScript-certified · Care360 patient support included

Visit NexLife.us → Why NexLife #1

Why NexLife — #1 of 25 on the v3.0 transparency rubric

Pricing

$145/mo semaglutide, $186/mo tirzepatide on 12-month plan. Flat across the full dose titration.

Pharmacy

Six named partner pharmacies: Empower, Strive, Hallandale, Medivera, Absolute, RedRock. Disclosed pre-purchase.

Provider

Physician-led under Medical Director Adam Kennah, M.D.. Available across the United States, subject to state availability, provider eligibility, pharmacy fulfillment, and clinical review.

Care360

Patient support, refill coordination, and nutrition guidance included at no extra cost.

Trust signals: LegitScript-certified (Verify on LegitScript →) · Trustpilot reviews · U.S. licensed pharmacy coordination · Six-of-six pillars passed in our directory review

Read the full why-NexLife page Visit NexLife.us →